Paclitaxel-2′-ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity

被引:22
作者
Tanino, Tadatoshi
Nawa, Akihiro
Kondo, Eisaku
Kikkawa, Fumitaka
Daikoku, Tohru
Tsurumi, Tatsuya
Luo, ChenHong
Nishiyama, Yukihiro
Takayanagi, Yuki
Nishimori, Katuhiko
Ichida, Seiji
Wada, Tetsuyuki
Miki, Yasuyoshi
Iwaki, Masahiro
机构
[1] Kinki Univ, Sch Pharmaceut Sci, Higashiosaka, Osaka 5778502, Japan
[2] Nagoya Univ, Grad Sch Med, Shouwa Ku, Nagoya, Aichi 4668550, Japan
[3] Aichi Canc Ctr, Res Inst, Chikusa Ku, Nagoya, Aichi 4648681, Japan
[4] Okayama Univ, Sch Med, Okayama 7008558, Japan
[5] Tohoku Univ, Grad Sch Agr Sci, Sendai, Miyagi 9818555, Japan
关键词
carboxylesterase-prodrug; gene-directed enzyme prodrug therapy; growth inhibition; paclitaxel; P-glycoprotein;
D O I
10.1007/s11095-006-9171-6
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose: The aim of the study was to investigate whether 2'-ethylcarbonate-linked paclitaxel (TAX-2'-Et) circumvents P-glycoprotein (P-gp)-mediated cellular efflux and cytotoxicity enhanced by TAX-2'-Et activation within human culture cells transfected with a rabbit liver carboxylesterase (Ra-CES) cDNA. Materials and Methods: TAX-2'-Et transport was characterized in a human colon carcinoma cell line (Caco-2) and paclitaxel (TAX)-resistant ovarian carcinoma cells (SKOV3/TAX60). Expression of P-gp, multidrug resistance protein (MRP) 2 and Ra-CES was detected by Western blotting. Cytotoxicity against Ra-CES-expressing cells and cellular amount of TAX produced were determined by MTT assay and using HPLC, respectively. Results: Unlike rhodamine123 and TAX, TAX-2'-Et did not exhibit polarized transport in the Caco-2 cells in the absence or presence of verapamil. P-gp levels were expressed much higher in the SKOV3/TAX60 cells than in the Caco-2 cells. MRP2 protein was not detectable in the SKOV3/TAX60 cells. Uptake by the SKOV3/TAX60 cells was similar in quantity to the amount internalized by P-gp-negative SKOV3 cells. In the SKOV3/TAX60 cells, cellular uptake of TAX-2'-Et was not altered regardless of the absence or presence of verapamil. The cytotoxicity to the untransfected SKOV3 cells induced by TAX-2'-Et was significantly lower than that induced by TAX. In the Ra-CES-expressing SKOV3 line, the EC50 value of TAX (10.6 nM) was approximately four-fold higher than that of TAX-2'-Et (2.5 nM). Transfection of Ra-CES into another TAX-resistant ovarian carcinoma cells (KOC-7c) conferred a high level of TAX-2'-Et cytotoxicity via prodrug activation. The intracellular levels of TAX produced from TAX-2'-Et in the Ra-CES-positive KOC-7c cells significantly increased compared with the levels seen in exposure of the untransfected KOC-7c cells to TAX. Conclusions: TAX-2'-Et can circumvent P-gp-associated cellular efflux of TAX. TAX-2'-Et is converted into TAX by the Ra-CES, supporting its potential use as a theoretical GDEPT strategy for cancer cells expressing high levels of P-gp. The TAX-2'-Et prodrug efficiently increased the amount of intracellular TAX, which mediates tumor cell death.
引用
收藏
页码:555 / 565
页数:11
相关论文
共 36 条
  • [21] Induction of human P-glycoprotein in Caco-2 cells: Development of a highly sensitive assay system for P-glycoprotein-mediated drug transport
    Shirasaka, Yoshiyuki
    Kawasaki, Masae
    Sakane, Toshiyasu
    Omatsu, Hideaki
    Moriya, Yuka
    Nakamura, Tsutomu
    Sakaeda, Toshiyuki
    Okumura, Katsuhiko
    Langguth, Peter
    Yamashita, Shinji
    DRUG METABOLISM AND PHARMACOKINETICS, 2006, 21 (05) : 414 - 423
  • [22] Discovery of a Flavonoid FM04 as a Potent Inhibitor to Reverse P-Glycoprotein-Mediated Drug Resistance in Xenografts and Improve Oral Bioavailability of Paclitaxel
    Kan, Jason W. Y.
    Yan, Clare S. W.
    Wong, Iris L. K.
    Su, Xiaochun
    Liu, Zhen
    Chan, Tak Hang
    Chow, Larry M. C.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (23)
  • [23] Circumvention of P-glycoprotein-mediated multidrug resistance by S16020-2: kinetics of uptake and efflux in sensitive and resistant cell lines
    A. Pierré
    S. Léonce
    V. Pérez
    G. Atassi
    Cancer Chemotherapy and Pharmacology, 1998, 42 : 454 - 460
  • [24] Circumvention of P-glycoprotein-mediated multidrug resistance by S16020-2:: kinetics of uptake and efflux in sensitive and resistant cell lines
    Pierré, A
    Léonce, S
    Pérez, V
    Atassi, G
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (06) : 454 - 460
  • [25] In vitro absorption and secretory quotients:: Practical criteria derived from a study of 331 compounds to assess for the impact of P-glycoprotein-mediated efflux on drug candidates
    Thiel-Demby, VE
    Tippin, TK
    Humphreys, JE
    Serabjit-Singh, CJ
    Polli, JW
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (10) : 2567 - 2572
  • [26] DRUG ABSORPTION LIMITED BY P-GLYCOPROTEIN-MEDIATED SECRETORY DRUG TRANSPORT IN HUMAN INTESTINAL EPITHELIAL CACO-2 CELL-LAYERS
    HUNTER, J
    HIRST, BH
    SIMMONS, NL
    PHARMACEUTICAL RESEARCH, 1993, 10 (05) : 743 - 749
  • [27] Efflux Ratio Cannot Assess P-Glycoprotein-Mediated Attenuation of Absorptive Transport: Asymmetric Effect of P-Glycoprotein on Absorptive and Secretory Transport Across Caco-2 Cell Monolayers
    Matthew D. Troutman
    Dhiren R. Thakker
    Pharmaceutical Research, 2003, 20 : 1200 - 1209
  • [28] Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: Asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers
    Troutman, MD
    Thakker, DR
    PHARMACEUTICAL RESEARCH, 2003, 20 (08) : 1200 - 1209
  • [29] ABSORPTION OF HYPACONITINE AND P-GLYCOPROTEIN-MEDIATED DRUG-HYPACONITINE INTERACTIONS BY CACO-2 HUMAN INTESTINAL CELL MONOLAYERS
    Han, Tianjiao
    Liu, Yang
    Pi, Zifeng
    Liu, Zhongying
    Song, Fengrui
    Liu, Zhiqiang
    JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 2013, 36 (09) : 1207 - 1220
  • [30] Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux
    Honda, Y
    Ushigome, F
    Koyabu, N
    Morimoto, S
    Shoyama, Y
    Uchiumi, T
    Kuwano, M
    Ohtani, H
    Sawada, Y
    BRITISH JOURNAL OF PHARMACOLOGY, 2004, 143 (07) : 856 - 864